SCHEMBL2120761

SCHEMBL2120761

Cc1ccc(-c2ccc(C#N)s2)cc1NS(=O)(=O)c1ccncc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 1/20 0.43
HSD17B2 P37059 1/20 0.43
SLC22A12 Q96S37 2/20 0.40
PIK3CA P42336 1/20 0.40
MTOR P42345 1/20 0.40
HSD11B1 P28845 2/20 0.39
PGR P06401 4/20 0.39
MAPT P10636 4/20 0.39
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 3/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
POLB P06746 1/20 0.38
HPGD P15428 3/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NR3C1 P04150 1/20 0.38
AR P10275 1/20 0.38
PIK3CG P48736 1/20 0.38
PRF1 P14222 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29498140 0.88 CYP2C9 (0.47) HSD17B1HSD17B2HSD11B1MAPTALDH1A1
SCHEMBL2117810 0.87 HSD17B1 (0.47) HSD17B1HSD17B2MAPTALDH1A1KDM4E
SCHEMBL2121470 0.84 HSD17B1 (0.44) HSD17B1HSD17B2HSD11B1PGRMAPT
SCHEMBL2118049 0.84 ALDH1A1 (0.40) HSD17B1HSD17B2PIK3CAMTORMAPT
SCHEMBL2119688 0.83 PRF1 (0.47) HSD11B1MAPTALDH1A1KDM4EMEN1
SCHEMBL2119515 0.82 CCR9 (0.40) HSD17B1HSD17B2PIK3CAMTORMAPT
SCHEMBL2117445 0.80 PGR (0.41) HSD17B1HSD17B2PGRMAPTALDH1A1
SCHEMBL2119262 0.79 MAPT (0.37) HSD17B1HSD17B2PIK3CAMTORPGR
SCHEMBL2119814 0.79 CCR2 (0.40) HSD17B1HSD17B2PGRMAPTALDH1A1
SCHEMBL2119666 0.79 GHSR (0.56) MAPTALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 HSD17B1 3605/4885HSD17B2 3889/4885SLC22A12 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.